Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
69.00
-0.18 (-0.26%)
Mar 9, 2026, 1:16 PM EDT - Market open
Inhibrx Biosciences Employees
As of December 31, 2024, Inhibrx Biosciences had 161 total employees, including 156 full-time and 5 part-time employees. The number of employees decreased by 11 or -6.40% compared to the previous year.
Employees
161
Change (1Y)
-11
Growth (1Y)
-6.40%
Revenue / Employee
$8,696
Profits / Employee
-$963,267
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 161 | -11 | -6.40% |
| Dec 31, 2023 | 172 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 596 |
| Pharming Group | 404 |
| Xeris Biopharma Holdings | 394 |
| UroGen Pharma | 287 |
| Geron | 229 |
| Cullinan Therapeutics | 111 |
| ArriVent BioPharma | 52 |
| GH Research | 50 |
INBX News
- 6 days ago - Inhibrx Announces Participation in Upcoming Scientific Conference - PRNewsWire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 7 weeks ago - Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too - Seeking Alpha
- 2 months ago - Why Inhibrx's Recent Strength May Not Be Built to Last - Benzinga
- 2 months ago - Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program - PRNewsWire
- 4 months ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 4 months ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 4 months ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha